NCT00314782 2013-03-12Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPCAstraZenecaPhase 1 Completed44 enrolled
NCT00090363 2013-01-08ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)AstraZenecaPhase 2 Completed447 enrolled 13 charts
NCT00055471 2012-10-31A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate CancerAstraZenecaPhase 2 Completed22 enrolled 17 charts